KR101800570B1 - 안질환을 처리하기 위한 고점성 거대분자 조성물 - Google Patents
안질환을 처리하기 위한 고점성 거대분자 조성물 Download PDFInfo
- Publication number
- KR101800570B1 KR101800570B1 KR1020167022920A KR20167022920A KR101800570B1 KR 101800570 B1 KR101800570 B1 KR 101800570B1 KR 1020167022920 A KR1020167022920 A KR 1020167022920A KR 20167022920 A KR20167022920 A KR 20167022920A KR 101800570 B1 KR101800570 B1 KR 101800570B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- retinal
- maac
- disease
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
| 성분 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 |
| 화합물 A | 0.5 mg | 1 mg | ||
| 소듐 히알루로네이트(평균 분자량 0.6x106 달톤) | 0.05% (w/v) |
0.5% (w/v) |
0.05% (w/v) |
0.5% (w/v) |
| 소듐 포스페이트 | 0.4% (w/v) | 0.4% (w/v) | 0.4% (w/v) | 0.4% (w/v) |
| 비타민 E-TPGS | 0.5% (w/v) | 0.5% (w/v) | 0.0 | 0.0 |
| 화합물 B | 0.5 mg | 1 mg | ||
| 주사용 물 | q.s. | q.s. | q.s. | q.s. |
| 전단 속도 0.1/초에서의 점도(25℃에서) | 20 cps | 500 cps | 20 cps | 500 cps |
| 성분 | 실시예 5 | 실시예 6 | 실시예 7 | 실시예 8 |
| 화합물 C | 0.5 mg | 1 mg | ||
| 소듐 히알루로네이트(평균 분자량 0.6x106 달톤) | 0.05% (w/v) |
0.5% (w/v) |
0.05% (w/v) |
0.5% (w/v) |
| 소듐 포스페이트 | 0.4% (w/v) | 0.4% (w/v) | 0.4% (w/v) | 0.4% (w/v) |
| 비타민 E-TPGS | 0.5% (w/v) | 0.5% (w/v) | 0.0 | 0.0 |
| 화합물 D | 0.5 mg | 1 mg | ||
| 주사용 물 | q.s. | q.s. | q.s. | q.s. |
| 전단 속도 0.1/초에서의 점도(25℃에서) | 20 cps | 500 cps | 20 cps | 500 cps |
| 성분 | 실시예 9 | 실시예 10 | 실시예 11 |
| 화합물 A | 0.5 mg | 1.0 mg | 2.0 mg |
| 소듐 히알루로네이트 | 3.0% (w/v) | 2.5% (w/v) | 2.0% (w/v) |
| 소듐 포스페이트 | 0.4% (w/v) | 0.4% (w/v) | 0.4% (w/v) |
| 주사용 물 | q.s. | q.s. | q.s. |
| 전단 속도 0.1/초에서의 점도(25℃에서) | 300,000 cps | 180,000 cps | 100,000 cps |
| 성분 | 실시예 12 | 실시예 13 |
| 화합물 D | 0.5 mg | 1 mg |
| 소듐 히알루로네이트 (중합체) | 2.5% (w/v) | 2.3% (w/v) |
| 소듐 클로라이드 | 0.63% (w/v) | 0.63% (w/v) |
| 2염기 소듐 포스페이트, 헵타하이드레이트 | 0.30% (w/v) | 0.30% (w/v) |
| 1염기 소듐 포스페이트, 모노하이드레이트 | 0.04% (w/v) | 0.04% (w/v) |
| 주사용 물 | q.s. | q.s. |
| 전단 속도 0.1/초에서의 점도(25℃에서) | 170,000 ± 25% cps | 200,000 ± 25% cps |
Claims (15)
- 혈관 내피 성장 인자 수용체-1(VEGFR-1)에 대한 친화성을 갖는 변형된 짧은 간섭 RNA(siRNA), 페갑타닙(pegaptanib), 라니비주맵(ranibozumab) 및 베바시주맵(bevacizumab)으로부터 선택된 치료학적으로 효과적인 양의 거대분자 항-신생혈관형성 성분(MAAC)을 포함하고 평균 분자량이 130만 내지 2백만 달톤인 히알루론산인 점도 유도 성분을 또한 포함하는 조성물을 함유하는, 미리-충전된 시린지이며,
상기 조성물은 25℃ 전단 속도 0.1/초에서 70,000 mPa·s (cps) 이상의 점도를 갖는 것인, 미리-충전된 시린지. - 제1항에 있어서, 상기 조성물이 용액의 형태인 미리-충전된 시린지.
- 제1항에 있어서, 상기 조성물이 젤의 형태인 미리-충전된 시린지.
- 제1항에 있어서, 상기 조성물이 현탁액의 형태인 미리-충전된 시린지.
- 삭제
- 제1항에 있어서, 상기 항-신생혈관형성 성분(MAAC)이 Cand5를 포함하는 것인, 미리-충전된 시린지.
- 제1항에 있어서, 상기 항-신생혈관형성 성분(MAAC)이 SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, 및 SEQ ID NO:10으로 이루어진 군으로부터 선택된 RNA 서열에 적어도 80% 상동성, 또는 적어도 90% 상동성, 또는 적어도 95% 상동성을 갖는 RNA 서열을 갖는 RNA를 적어도 하나 이상 포함하는 것인, 미리-충전된 시린지.
- 삭제
- 삭제
- 제1항에 있어서, 상기 점도 유도 성분이 25℃ 전단 속도 0.1/초에서 적어도 200,000 mPa·s (cps), 또는 25℃ 전단 속도 0.1/초에서 적어도 250,000 mPa·s (cps), 또는 25℃ 전단 속도 0.1/초에서 적어도 300,000 mPa·s (cps)의 점도를 갖는 것인, 미리-충전된 시린지.
- 삭제
- 제1항에 있어서, 상기 조성물이 안질환을 치료하는 방법에 사용되는 것인, 미리-충전된 시린지.
- 제12항에 있어서, 안질환의 치료가 상기 조성물을 27-게이지 니들을 통해서, 또는 30-게이지 니들을 통해서 후안부로 배치하여 눈의 안쪽에 투여하는 것을 포함하는, 미리-충전된 시린지.
- 제12항에 있어서, 상기 안질환이 후안부 질환인 미리-충전된 시린지.
- 제12항에 있어서, 상기 안질환이 비-삼출성 노인성 황반 변성, 삼출성 노인성 황반변성을 포함하는 황반 변성, 맥락막 혈관신생(choroidal neovascularization), 망막증, 당뇨병성 망막증, 급성 및 만성 황반성 신경망막병증(acute Macular Neuroretinopathy), 중심성 장액성 맥락망막병증(central serous chorioretinopathy), 황반 부종, 급성 다발성 판상색소 상피증(acute multifocal placoid epitheliopathy), 베체트 병, 버드샷 망막맥락막증(birdshot retinochoroidopathy), 후공막염(posterior scleritis), 사행성 맥락막염(serpiginous choroiditis), 망막하 섬유화(subretinal fibrosis), 포도막염 증후군(uveitis syndrome), 보그트-고야나기-하라다 증후군(Vogt-Koyanagi-and Harada syndrome), 망막동맥폐색병(retinal arterial occlusive disease), 중심성 망막 정맥 폐색(central retinal vein occlusion), 파종성 혈관내응고증 (disseminated intravascular coagulopathy), 분지성 망막 정맥 폐색(branch retinal vein occlusion), 고혈압성 안저변화(hypertensive fundus changes), 안허혈 증후군(ocular ischemic syndrome), 망막 동맥 미세혈관류(retinal arterial microaneurysms), 코우츠 병(Coat's disease), 중심오목부근 모세혈관확장증(parafoveal telangiectasis), 반측 망막정맥폐색(hemi-retinal vein occlusion), 유두정맥염(papillophlebitis), 중심성 망막 동맥 폐색(central retinal artery occlusion), 분지성 망막 동맥 폐색(branch retinal artery occlusion), 경동맥 질환(CAD), 언가지모양혈관염(frosted branch angitis), 겸상세포 망막증(sickle cell retinopathy), 혈관무늬 망막증(angioid streaks), 가족성 삼출 유리체망막증(familial exudative vitreoretinopathy), 일스 병(Eales disease), 증식성 유리체 망막증, 증식성 당뇨병성 망막증, 종양과 관련된 망막 질환, 망막 색소 상피(RPE)의 선천성 비후(congenital hypertrophy), 후부 포도막 흑색종(posterior uveal melanoma), 맥락막 혈관종(choroidal hemangioma), 맥락막 골종(choroidal osteoma), 맥락막 전이, 망막 및 망막 색소 상피의 복합 과오종(combined hamartoma of the retina and retinal pigmented epithelium), 망막아세포종, 안저의 혈관증식성 종양(vasoproliferative tumors of the ocular fundus), 망막별아교세포종(retinal astrocytoma), 안내 림프성 종양, 근시성 망막 변성 및 급성 망막 색소 상피염(retinal pigement epithelitis)로 이루어진 군으로부터 선택되는 미리-충전된 시린지.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/742,350 US11078262B2 (en) | 2007-04-30 | 2007-04-30 | High viscosity macromolecular compositions for treating ocular conditions |
| US11/742,350 | 2007-04-30 | ||
| PCT/US2008/061785 WO2008134644A1 (en) | 2007-04-30 | 2008-04-28 | High viscosity macromolecular compositions for treating ocular conditions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097024897A Division KR101652114B1 (ko) | 2007-04-30 | 2008-04-28 | 안질환을 처리하기 위한 고점성 거대분자 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160103174A KR20160103174A (ko) | 2016-08-31 |
| KR101800570B1 true KR101800570B1 (ko) | 2017-11-22 |
Family
ID=39532784
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167022920A Expired - Fee Related KR101800570B1 (ko) | 2007-04-30 | 2008-04-28 | 안질환을 처리하기 위한 고점성 거대분자 조성물 |
| KR1020097024897A Expired - Fee Related KR101652114B1 (ko) | 2007-04-30 | 2008-04-28 | 안질환을 처리하기 위한 고점성 거대분자 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097024897A Expired - Fee Related KR101652114B1 (ko) | 2007-04-30 | 2008-04-28 | 안질환을 처리하기 위한 고점성 거대분자 조성물 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11078262B2 (ko) |
| EP (3) | EP2446890B1 (ko) |
| JP (3) | JP5775301B2 (ko) |
| KR (2) | KR101800570B1 (ko) |
| AT (1) | ATE554747T1 (ko) |
| AU (1) | AU2008245503B2 (ko) |
| BR (1) | BRPI0810715B8 (ko) |
| CA (1) | CA2685522C (ko) |
| ES (3) | ES2386847T3 (ko) |
| WO (1) | WO2008134644A1 (ko) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| US8586556B2 (en) * | 2006-11-03 | 2013-11-19 | Allergan, Inc. | Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| US8642067B2 (en) * | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| CA2687990A1 (en) | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
| US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
| PT2818184T (pt) | 2007-11-16 | 2019-01-28 | Aclaris Therapeutics Inc | Composições e métodos para o tratamento de púrpura |
| US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US9044477B2 (en) | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| EP2247615B1 (en) | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| JP2011517451A (ja) | 2008-03-28 | 2011-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ポリペプチド−ポリマー抱合体およびその使用方法 |
| AR071874A1 (es) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| MX2011000247A (es) * | 2008-07-10 | 2011-03-30 | Inspire Pharmaceuticals Inc | Composicion farmaceutica para el tratamiento de blefaritis. |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| CA2735173C (en) | 2008-09-02 | 2017-01-10 | Tautona Group Lp | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| US20100098772A1 (en) * | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
| WO2010085572A1 (en) * | 2009-01-23 | 2010-07-29 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with azithromycin |
| WO2010097800A1 (en) * | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| RU2567639C2 (ru) * | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| AU2011217785B2 (en) | 2010-02-19 | 2015-06-18 | The Regents Of The University Of California | Epithelial membrane protein 2 (EMP2) binding reagents and their therapeutic uses in ocular diseases |
| US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
| EP4062950A1 (en) | 2010-03-22 | 2022-09-28 | Allergan, Inc. | Syringe comprising dermal filler for soft tissue augmentation |
| EP3091028A1 (en) | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| WO2012012541A2 (en) | 2010-07-21 | 2012-01-26 | Allergan, Inc. | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20120058187A1 (en) * | 2010-09-03 | 2012-03-08 | Novagali Pharma Sa | Water-in-oil type emulsion for treating a disease of the eye |
| US9107822B2 (en) * | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
| RU2624239C2 (ru) | 2011-06-03 | 2017-07-03 | Аллерган, Инк. | Составы кожного наполнителя, включая антиоксиданты |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| GB201117538D0 (en) * | 2011-10-11 | 2011-11-23 | Royal Veterinary College The | Methods |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| US8912215B2 (en) | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| WO2014052518A1 (en) | 2012-09-27 | 2014-04-03 | Allergan, Inc. | Biodegradable drug delivery systems for the sustained release of proteins |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| JP6572201B2 (ja) | 2013-03-15 | 2019-09-04 | エアーピオ セラピューティクス インコーポレイテッド | 眼疾患を処置するための組成物、製剤、および方法 |
| EP3702461A1 (en) * | 2013-07-08 | 2020-09-02 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof |
| WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| WO2015142853A1 (en) | 2014-03-17 | 2015-09-24 | Encompass Development, Inc. | Ocular formulations |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| WO2016051219A1 (en) | 2014-09-30 | 2016-04-07 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
| WO2016128783A1 (en) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
| RU2715234C2 (ru) | 2015-02-13 | 2020-02-26 | Аллерган Эндюстри, Сас | Имплантаты для моделирования, увеличения или коррекции частей лица, например подбородка |
| CN108135737B (zh) | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| JP6959912B2 (ja) | 2015-09-23 | 2021-11-05 | ジェネンテック, インコーポレイテッド | 抗vegf抗体の最適化変異体 |
| KR102944785B1 (ko) | 2015-12-09 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 질환 또는 장애의 치료 방법 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| US10973867B2 (en) | 2015-12-30 | 2021-04-13 | Marshall University Research Corporation | Compositions and methods for treating retinopathy |
| KR102179241B1 (ko) * | 2016-04-22 | 2020-11-16 | 국립암센터 | 병변 표지용 주사제 조성물 |
| BR112018074450A2 (pt) * | 2016-06-02 | 2019-03-19 | Cloudbreak Therapeutics, Llc | composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma |
| WO2018183984A1 (en) * | 2017-03-31 | 2018-10-04 | Rowan University | Optically clear, in-situ forming biodegradable nano-carriers for ocular therapy, and methods using same |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| KR102954778B1 (ko) | 2018-03-09 | 2026-04-20 | 발리터 인코포레이티드 | 관절 염증의 지속적인 관절내 치료를 위한 다가 펩티드 컨쥬게이트 |
| AU2019256289A1 (en) * | 2018-04-17 | 2020-11-12 | Outlook Therapeutics, Inc. | Buffered formulations of bevacizumab for use of treating diseases |
| CN110755427A (zh) * | 2018-07-28 | 2020-02-07 | 华中科技大学 | 一种治疗视网膜退行性疾病的药物 |
| IT201800007683A1 (it) | 2018-07-31 | 2020-01-31 | Altergon Sa | Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati |
| CN113164551A (zh) * | 2018-10-24 | 2021-07-23 | 雅利斯塔制药公司 | 脂联素肽模拟物制剂 |
| JP7564824B2 (ja) | 2019-04-29 | 2024-10-09 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
| DE102019112917B4 (de) * | 2019-05-16 | 2021-07-22 | Carl Zeiss Meditec Ag | Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat |
| CN110025768B (zh) * | 2019-06-03 | 2023-03-21 | 上海市第一人民医院 | 一种眼部疾病动物模型的构建方法及其应用 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| UY38819A (es) * | 2019-08-01 | 2021-02-26 | Gennova Biopharmaceuticals Ltd | Composición oftálmica de bevacizumab |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20240156839A1 (en) * | 2021-03-05 | 2024-05-16 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions with reduced side effect and methods of using the same |
| US20220387554A1 (en) * | 2021-06-04 | 2022-12-08 | Mark H. Nelson | Treatments for exudative maculopathies |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| US20230310380A1 (en) * | 2022-04-05 | 2023-10-05 | Alan Neil Glazier | Methods, devices, and systems for treating lens protein aggregation diseases |
| CN115040535B (zh) * | 2022-08-15 | 2022-12-16 | 华南理工大学 | 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN118903383B (zh) * | 2024-10-09 | 2025-02-25 | 中山大学中山眼科中心 | Vegf-b蛋白、vegf-b蛋白活性肽段在制备预防和/或治疗急性前葡萄膜炎的药物中的应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US166331A (en) | 1875-08-03 | Improvement in motors | ||
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| AU604236B2 (en) | 1986-04-28 | 1990-12-13 | Iolab, Inc. | Intraocular dosage compositions and method of use |
| JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| ATE256143T1 (de) | 1992-07-23 | 2003-12-15 | Isis Pharmaceuticals Inc | 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
| EP0689460A4 (en) | 1993-02-19 | 1996-11-13 | Isis Pharmaceuticals Inc | CYCLOBUTYL ANTISIN OLIGONUCLEOTIDES, PRODUCTION METHODS AND USE THEREOF |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| JP3208525B2 (ja) | 1995-01-05 | 2001-09-17 | 電気化学工業株式会社 | ヒアルロン酸ナトリウム溶液注射剤および注射用容器 |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050233344A1 (en) | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
| EP1627061B1 (en) | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2005500025A (ja) | 2001-05-29 | 2005-01-06 | サーナ・セラピューティクス・インコーポレイテッド | 女性生殖疾病及び状態の核酸に基づく調節 |
| WO2003000856A2 (en) | 2001-06-21 | 2003-01-03 | Phylos, Inc. | In vitro protein interaction detection systems |
| ATE507816T1 (de) | 2001-11-14 | 2011-05-15 | Durect Corp | Injizierbare depotzusammensetzungen und deren verwendung |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| US20050074865A1 (en) | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| WO2004029224A2 (en) | 2002-09-30 | 2004-04-08 | Compound Therapeutics, Inc. | Methods of engineering spatially conserved motifs in polypeptides |
| US7399612B2 (en) * | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| JP2007505932A (ja) | 2003-09-18 | 2007-03-15 | マクサイト, インコーポレイテッド | 経強膜送達 |
| EP1675949A2 (en) | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| ATE452188T1 (de) | 2004-02-10 | 2010-01-15 | Sirna Therapeutics Inc | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| WO2006043965A1 (en) | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| JP5122460B2 (ja) | 2005-09-16 | 2013-01-16 | アラーガン、インコーポレイテッド | 治療薬の眼内輸送のための組成物および方法 |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| MX339797B (es) | 2005-10-18 | 2016-06-10 | Allergan Inc | Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. |
| ES2385924T3 (es) * | 2006-02-02 | 2012-08-03 | Allergan, Inc. | Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US9197705B2 (en) | 2013-04-12 | 2015-11-24 | Samsung Electronics Co., Ltd. | Method and apparatus for supporting driving using wireless communication network and system thereof |
-
2007
- 2007-04-30 US US11/742,350 patent/US11078262B2/en not_active Expired - Fee Related
-
2008
- 2008-04-28 AT AT08747032T patent/ATE554747T1/de active
- 2008-04-28 WO PCT/US2008/061785 patent/WO2008134644A1/en not_active Ceased
- 2008-04-28 ES ES08747032T patent/ES2386847T3/es active Active
- 2008-04-28 KR KR1020167022920A patent/KR101800570B1/ko not_active Expired - Fee Related
- 2008-04-28 KR KR1020097024897A patent/KR101652114B1/ko not_active Expired - Fee Related
- 2008-04-28 EP EP12151895.5A patent/EP2446890B1/en not_active Not-in-force
- 2008-04-28 BR BRPI0810715A patent/BRPI0810715B8/pt not_active IP Right Cessation
- 2008-04-28 EP EP12199057.6A patent/EP2606899B1/en not_active Revoked
- 2008-04-28 CA CA2685522A patent/CA2685522C/en active Active
- 2008-04-28 ES ES12199057.6T patent/ES2541292T3/es active Active
- 2008-04-28 EP EP08747032A patent/EP2146727B1/en not_active Not-in-force
- 2008-04-28 AU AU2008245503A patent/AU2008245503B2/en not_active Ceased
- 2008-04-28 ES ES12151895T patent/ES2436203T3/es active Active
- 2008-04-28 JP JP2010506560A patent/JP5775301B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-06 JP JP2013185340A patent/JP6165565B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-16 JP JP2015224266A patent/JP6247272B2/ja not_active Expired - Fee Related
-
2021
- 2021-08-02 US US17/392,252 patent/US20220106388A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Gene Ther. 13(3):225-34 (2006.02.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2606899B1 (en) | 2015-04-15 |
| EP2446890A1 (en) | 2012-05-02 |
| EP2446890B1 (en) | 2013-09-18 |
| US20080268051A1 (en) | 2008-10-30 |
| EP2606899A1 (en) | 2013-06-26 |
| EP2146727B1 (en) | 2012-04-25 |
| BRPI0810715B8 (pt) | 2021-05-25 |
| BRPI0810715B1 (pt) | 2021-01-19 |
| JP2010526780A (ja) | 2010-08-05 |
| CA2685522C (en) | 2018-06-12 |
| JP2014005288A (ja) | 2014-01-16 |
| JP6165565B2 (ja) | 2017-07-19 |
| WO2008134644A1 (en) | 2008-11-06 |
| ES2541292T3 (es) | 2015-07-17 |
| AU2008245503B2 (en) | 2014-01-23 |
| AU2008245503A1 (en) | 2008-11-06 |
| JP6247272B2 (ja) | 2017-12-13 |
| JP2016040313A (ja) | 2016-03-24 |
| JP5775301B2 (ja) | 2015-09-09 |
| HK1184683A1 (en) | 2014-01-30 |
| KR20100022964A (ko) | 2010-03-03 |
| BRPI0810715A2 (pt) | 2016-07-26 |
| KR101652114B1 (ko) | 2016-09-06 |
| ES2436203T3 (es) | 2013-12-27 |
| CA2685522A1 (en) | 2008-11-06 |
| ATE554747T1 (de) | 2012-05-15 |
| US20220106388A1 (en) | 2022-04-07 |
| KR20160103174A (ko) | 2016-08-31 |
| US11078262B2 (en) | 2021-08-03 |
| EP2146727A1 (en) | 2010-01-27 |
| ES2386847T3 (es) | 2012-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220106388A1 (en) | High viscosity macromolecular compositions for treating ocular conditions | |
| US8642067B2 (en) | Methods and compositions for intraocular administration to treat ocular conditions | |
| US8591885B2 (en) | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems | |
| US20060182783A1 (en) | Sustained release intraocular drug delivery systems | |
| US20070059336A1 (en) | Anti-angiogenic sustained release intraocular implants and related methods | |
| US20230279090A1 (en) | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery | |
| AU2017202760B2 (en) | High viscosity macromolecular compositions for treating ocular conditions | |
| HK1184683B (en) | High viscosity macromolecluar compositions for treating ocular conditions | |
| RU2776850C2 (ru) | Способы лечения глазных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20241117 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE Effective date: 20241117 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20241117 |